Natural killer group 2D and CD28 receptors differentially activate mammalian/mechanistic target of rapamycin to alter murine effector CD8+ T-cell differentiation

Immunology

Volumn 147, Issue 3, 2016, Pages 305-320

  Mcqueen, Bryan ^a   Trace, Kelsey ^a   Whitman, Emily ^a   Bedsworth, Taylor ^a   Barber, Amorette ^a  

^a LONGWOOD UNIVERSITY   (United States)

Author keywords

CD8 T cells; Co stimulation; Immunotherapy; Mammalian mechanistic target of rapamycin; Natural killer group 2D

Indexed keywords

B LYMPHOCYTE INDUCED MATURATION PROTEIN 1; CD28 ANTIGEN; CD28 RECEPTOR; CD3 ANTIGEN; HYPOXIA INDUCIBLE FACTOR 1ALPHA; INHIBITOR OF DIFFERENTIATION 2; INHIBITOR OF DIFFERENTIATION 3; INITIATION FACTOR 4E BINDING PROTEIN 1; INTERFERON REGULATORY FACTOR 4; INTERLEUKIN 7 RECEPTOR; L SELECTIN; MAMMALIAN TARGET OF RAPAMYCIN; MAMMALIAN TARGET OF RAPAMYCIN COMPLEX 1; NATURAL KILLER CELL RECEPTOR NKG2D; PROTEIN BCL 6; PROTEIN S6; RECEPTOR; TRANSCRIPTION FACTOR T BET; TUBERIN; UNCLASSIFIED DRUG; VASCULAR ENDOTHELIAL CELL GROWTH FACTOR ALPHA; VASCULOTROPIN; KLRK1 PROTEIN, MOUSE; MTOR PROTEIN, MOUSE; NATURAL KILLER CELL LECTIN LIKE RECEPTOR SUBFAMILY K; TARGET OF RAPAMYCIN KINASE;

ANIMAL CELL; ARTICLE; CD8+ T LYMPHOCYTE; CONTROLLED STUDY; EFFECTOR CELL; ENZYME LINKED IMMUNOSORBENT ASSAY; GENE EXPRESSION; IMMUNOLOGICAL MEMORY; LYMPHOCYTE DIFFERENTIATION; MALE; MOUSE; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; REAL TIME POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; ANIMAL; C57BL MOUSE; CELL DIFFERENTIATION; FLOW CYTOMETRY; GENE EXPRESSION REGULATION; IMMUNOLOGY; LYMPHOCYTE ACTIVATION;

ANIMALS; ANTIGENS, CD28; CD8-POSITIVE T-LYMPHOCYTES; CELL DIFFERENTIATION; ENZYME-LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; GENE EXPRESSION REGULATION; LYMPHOCYTE ACTIVATION; MALE; MICE; MICE, INBRED C57BL; NK CELL LECTIN-LIKE RECEPTOR SUBFAMILY K; REAL-TIME POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; TOR SERINE-THREONINE KINASES;

EID: 84958628238     PISSN: 00192805     EISSN: 13652567     Source Type: Journal    
DOI: 10.1111/imm.12563     Document Type: Article

References (70)

1. Sarkar S, Kalia V, Haining WN, Konieczny BT, Subramaniam S, Ahmed R. Functional and genomic profiling of effector CD8 T cell subsets with distinct memory fates. J Exp Med 2008; 205:625-40.
2. Obar JJ, Lefrancois L. Early events governing memory CD8 T-cell differentiation. Int Immunol 2010; 22:619-25.
3. Amsen D, Backer RA, Helbig C. Decisions on the road to memory. Adv Exp Med Biol 2013; 785:107-20.
4. + T cell differentiation. Nat Rev Immunol 2012; 12:749-61.
5. Kaech SM, Tan JT, Wherry EJ, Konieczny BT, Surh CD, Ahmed R. Selective expression of the interleukin 7 receptor identifies effector CD8 T cells that give rise to long-lived memory cells. Nat Immunol 2003; 4:1191-8.
6. + T cells after infection. Nat Immunol 2002; 3:619-26.
7. + T cell fate coupled by T-bet and eomesodermin. Nat Immunol 2005; 6:1236-44.
8. + T cell fates via the graded expression of T-bet transcription factor. Immunity 2007; 27:281-95.
9. + T cells and memory responses. Immunity 2009; 31:283-95.
10. + T cell terminal differentiation and represses the acquisition of central memory T cell properties. Immunity 2009; 31:296-308.
11. Crotty S, Johnston RJ, Schoenberger SP. Effectors and memories: Bcl-6 and Blimp-1 in T and B lymphocyte differentiation. Nat Immunol 2010; 11:114-20.
12. + T cells depend on T cell factor 1. Immunity 2010; 33:229-40.
13. + T cell expansion and effector differentiation. Immunity 2013; 39:833-45.
14. Man K, Miasari M, Shi W, Xin A, Henstridge DC, Preston S et al. The transcription factor IRF4 is essential for TCR affinity-mediated metabolic programming and clonal expansion of T cells. Nat Immunol 2013; 14:1155-65.
15. + T cells. Nat Immunol 2011; 12:1230-7.
16. + T cell immunity. Nat Immunol 2006; 7:1317-25.
17. + T cell subsets. Nat Immunol 2011; 12:1221-9.
18. Araki K, Turner AP, Shaffer VO, Gangappa S, Keller SA, Bachmann MF et al. mTOR regulates memory CD8 T-cell differentiation. Nature 2009; 460:108-12.
19. Delgoffe GM, Kole TP, Zheng Y, Zarek PE, Matthews KL, Xiao B et al. mTOR differentially regulates effector and regulatory T cell lineage commitment. Immunity 2009; 30:832-44.
20. Araki K, Youngblood B, Ahmed R. The role of mTOR in memory CD8 T-cell differentiation. Immunol Rev 2010; 235:234-43.
21. + T cell fate by regulating the expression of transcription factors T-bet and eomesodermin. Immunity 2010; 32:67-78.
22. + T cell memory and tumor immunity. Immunity 2011; 34:541-53.
23. Chi H. Regulation and function of mTOR signalling in T cell fate decisions. Nat Rev Immunol 2012; 12:325-38.
24. Chapman NM, Chi H. mTOR links environmental signals to T cell fate decisions. Front Immunol 2015; 5:686.
25. + T cells via orchestrating the transcriptional and metabolic programs. Proc Natl Acad Sci USA 2014; 111:14858-63.
26. + T cell differentiation. J Clin Invest 2015; 125:2090-108.
27. Berezhnoy A, Castro I, Levay A, Malek TR, Gilboa E. Aptamer-targeted inhibition of mTOR in T cells enhances antitumor immunity. J Clin Invest 2014; 124:188-97.
28. Krishna S, Yang J, Wang H, Qiu Y, Zhong XP. Role of tumor suppressor TSC1 in regulating antigen-specific primary and memory CD8 T cell responses to bacterial infection. Infect Immun 2014; 82:3045-57.
29. Shrikant PA, Rao R, Li Q, Kesterson J, Eppolito C, Mischo A et al. Regulating functional cell fates in CD8 T cells. Immunol Res 2010; 46:12-22.
30. + T cells during viral infections. Crit Rev Immunol 2009; 29:469-86.
31. + T cell fates. Curr Opin Immunol 2013; 25:321-8.
32. Pipkin ME, Sacks JA, Cruz-Guilloty F, Lichtenheld MG, Bevan MJ, Rao A. Interleukin-2 and inflammation induce distinct transcriptional programs that promote the differentiation of effector cytolytic T cells. Immunity 2010; 32:79-90.
33. + T cells favors terminal-effector differentiation in vivo. Immunity 2010; 32:91-103.
34. Champsaur M, Lanier LL. Effect of NKG2D ligand expression on host immune responses. Immunol Rev 2011; 235:267-85.
35. Zhang J, Basher F, Wu JD. NKG2D Ligands in tumor immunity. Front Immunol 2015; 6:97.
36. Mistry AR, O'Callaghan CA. Regulation of ligands for the activating receptor NKG2D. Immunology 2007; 121:439-47.
37. Groh V, Rhinehart R, Randolph-Habecker J, Topp MS, Riddell SR, Spies T. Costimulation of CD8αβ T cells by NKG2D via engagement by MIC induced on virus-infected cells. Nat Immunol 2001; 2:255-60.
38. + T cells. J Immunol 2005; 174:4480-4.
39. + CTL function: similarities and differences between NKG2D and CD28 costimulation. J Immunol 2005; 175:2825-33.
40. Lanier LL. NKG2D receptor and its ligands in host defense. Cancer Immunol Res 2015; 3:575-82.
41. Benitez AC, Dai Z, Mann HH, Reeves RS, Margineantu DH, Gooley TA et al. Expression, signaling proficiency, and stimulatory function of the NKG2D lymphocyte receptor in human cancer cells. Proc Natl Acad Sci USA 2011; 108:4081-6.
42. Kim EH, Sullivan JA, Plisch EH, Tejera MM, Jatzek A, Choi KY et al. Signal integration by Akt regulates CD8 T cell effector and memory differentiation. J Immunol 2012; 188:4305-14.
43. Colombetti S, Basso V, Mueller DL, Mondino A. Prolonged TCR/CD28 engagement drives IL-2- independent T cell clonal expansion through signaling mediated by the mammalian target of rapamycin. J Immunol 2006; 176:2730-8.
44. Upshaw JL, Leibson PJ. NKG2D-mediated activation of cytotoxic lymphocytes: unique signaling pathways and distinct functional outcomes. Semin Immunol 2006; 18:167-75.
45. + T cells. PLoS ONE 2010; 5:e12635.
46. Barber A, Sentman CL. NKG2D receptor regulates human effector T-cell cytokine production. Blood 2011; 117:6571-81.
47. + T cells. Mol Immunol 2015; 63:268-78.
48. Chu T, Tyznik AJ, Roepke S, Berkley AM, Woodward-Davis A, Pattacini L et al. Bystander-activated memory CD8 T cells control early pathogen load in an innate-like, NKG2D-dependent manner. Cell Rep 2013; 3:701-8.
49. Wensveen FM, Lenartic M, Jelencic V, Lemmermann NA, ten Brinke A, Jonjic S et al. NKG2D induces Mcl-1 expression and mediates survival of CD8 memory T cell precursors via phosphatidylinositol 3-kinase. J Immunol 2013; 191:1307-15.
50. + T cell memory recall but not effector responses. Nat Med 2012; 18:422-8.
51. Gamper CJ, Powell JD. All PI3Kinase signaling is not mTOR: dissecting mTOR-dependent and independent signaling pathways in T cells. Front Immunol 2012; 3:312.
52. Xu X, Ye L, Araki K, Ahmed R. mTOR, linking metabolism and immunity. Semin Immunol 2012; 24:429-35.
53. Ramsay G, Cantrell D. Environmental and metabolic sensors that control T cell biology. Front Immunol 2015; 6:99.
54. Brunet A, Justin P, Tran H, Hu LS, Hemmings BA, Greenberg ME. Protein kinase SGK mediates survival signals by phosphorylating the forkhead transcription factor FKHRL1 (FOXO3a). Mol Cell Biol 2001; 21:952-65.
55. Inoki K, Ouyang H, Zhu T, Lindvall C, Wang Y, Zhang X et al. TSC2 integrates Wnt and energy signals via a coordinated phosphorylation by AMPK and GSK3 to regulate cell growth. Cell 2006; 126:955-68.
56. Di Pietro N, Panel V, Hayes S, Bagattin A, Meruvu S, Pandolfi A et al. Serum- and glucocorticoid-inducible kinase 1 (SGK1) regulates adipocyte differentiation via forkhead box O1. Mol Endocrinol 2010; 24:370-80.
57. Heikamp EB, Patel CH, Collins S, Waickman A, Oh MH, Sun IH et al. The AGC kinase SGK1 regulates TH1 and TH2 differentiation downstream of the mTORC2 complex. Nat Immunol 2014; 15:457-64.
58. Wu C, Yosef N, Thalhamer T, Zhu C, Xiao S, Kishi Y et al. Induction of pathogenic TH17 cells by inducible salt-sensing kinase SGK1. Nature 2013; 496:513-7.
59. Zeng H, Chi H. mTOR signaling and transcriptional regulation in T lymphocytes. Transcription 2014; 5:e28263.
60. Foster DA, Toschi A. Targeting mTOR with rapamycin: one dose does not fit all. Cell Cycle 2009; 8:1026-9.
61. Nakamura H, Makino Y, Okamoto K, Poellinger L, Ohnuma K, Morimoto C et al. TCR engagement increases hypoxia-inducible factor-1α protein synthesis via rapamycin-sensitive pathway under hypoxic conditions in human peripheral T cells. J Immunol 2005; 174:7592-9.
62. Zhang T, Barber A, Sentman CL. Chimeric NKG2D modified T cells inhibit systemic T-cell lymphoma growth in a manner involving multiple cytokines and cytotoxic pathways. Cancer Res 2007; 67:11029-36.
63. + memory stem cells. Nat Med 2009; 15:808-13.
64. Prlic M, Bevan MJ. Β-catenin is dispensable for T cell effector differentiation, memory formation, and recall responses. J Immunol 2011; 187:1542-6.
65. Willoughby JE, Kerr JP, Rogel A, Taraban VY, Buchan SL, Johnson PW et al. Differential impact of CD27 and 4-1BB costimulation on effector and memory CD8 T cell generation following peptide immunization. J Immunol 2014; 193:244-51.
66. Capece D, Verzella D, Fischietti M, Zazzeroni F, Alesse E. Targeting costimulatory molecules to improve antitumor immunity. J Biomed Biotechnol 2012; 2012:e926321.
67. Figueroa JA, Reidy A, Mirandola L, Trotter K, Suvorava N, Figueroa A et al. Chimeric antigen receptor engineering: a right step in the evolution of adoptive cellular immunotherapy. Rev Immunol 2015; 34:154-87.
68. Barber A, Zhang T, Sentman CL. Immunotherapy with chimeric NKG2D receptors leads to long-term tumor-free survival and development of host antitumor immunity in murine ovarian cancer. J Immunol 2008; 180:72-8.
69. Slavuljica I, Busche A, Babić M, Mitrovic M, Gasparovic I, Cekinovic D et al. Recombinant mouse cytomegalovirus expressing a ligand for the NKG2D receptor is attenuated and has improved vaccine properties. J Clin Invest 2010; 120:4532-45.
70. Trsan T, Busche A, Abram M, Wensveen FM, Lemmermann NA, Arapovic M et al. Superior induction and maintenance of protective CD8 T cells in mice infected with mouse cytomegalovirus vector expressing RAE-1γ. Proc Natl Acad Sci USA 2013; 110:16550-5.